ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer’s Disease, enhancing program’s potential for priority review

PRECISE-AD Phase 1b Trial in Alzheimer’s Disease Progressing on Schedule: Over 50% enrolled, no cases of ARIA and no patient dropouts to date

Read more at globenewswire.com